CY1119231T1 - Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 - Google Patents

Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3

Info

Publication number
CY1119231T1
CY1119231T1 CY20171100737T CY171100737T CY1119231T1 CY 1119231 T1 CY1119231 T1 CY 1119231T1 CY 20171100737 T CY20171100737 T CY 20171100737T CY 171100737 T CY171100737 T CY 171100737T CY 1119231 T1 CY1119231 T1 CY 1119231T1
Authority
CY
Cyprus
Prior art keywords
gsk
thiadiazolidinodiones
suspensions
diseases
thiadiazolidinediones
Prior art date
Application number
CY20171100737T
Other languages
Greek (el)
English (en)
Inventor
Padilla Miguel Medina
Correa Juan Manuel Domínguez
Cristobal Blanco Javier De
Huerta Ana Fuertes
Jorge Sánchez-Quesada
Ogalla Javier López
Santos Susana Herrero
De La Cruz Moreno María Ángeles Pérez
Montero Olga Martínez
Salguero Beatriz Rodríguez
Nicolau Francisco Palomo
Original Assignee
Asd Therapeutics Partners Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asd Therapeutics Partners Llc filed Critical Asd Therapeutics Partners Llc
Publication of CY1119231T1 publication Critical patent/CY1119231T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20171100737T 2012-02-24 2017-07-12 Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 CY1119231T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382066 2012-02-24
PCT/EP2013/053554 WO2013124413A1 (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors
EP13705492.0A EP2838888B1 (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
CY1119231T1 true CY1119231T1 (el) 2018-02-14

Family

ID=47747639

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100737T CY1119231T1 (el) 2012-02-24 2017-07-12 Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3

Country Status (18)

Country Link
US (2) US9371299B2 (enExample)
EP (1) EP2838888B1 (enExample)
JP (2) JP6073377B2 (enExample)
AU (2) AU2013224041B2 (enExample)
CA (1) CA2865351C (enExample)
CY (1) CY1119231T1 (enExample)
DK (1) DK2838888T3 (enExample)
ES (1) ES2632428T3 (enExample)
HR (1) HRP20170964T1 (enExample)
HU (1) HUE035089T2 (enExample)
IN (1) IN2014DN07885A (enExample)
LT (1) LT2838888T (enExample)
NZ (1) NZ630615A (enExample)
PL (1) PL2838888T3 (enExample)
PT (1) PT2838888T (enExample)
SI (1) SI2838888T1 (enExample)
WO (1) WO2013124413A1 (enExample)
ZA (1) ZA201406225B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2838888B1 (en) 2012-02-24 2017-04-12 ASD Therapeutics Partners LLC Thiadiazolidinediones as gsk-3 inhibitors
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
MX388409B (es) * 2014-06-12 2025-03-19 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
CN113168150B (zh) * 2018-10-16 2024-05-10 意大利技术联盟有限责任公司 具有被处理幅材的评估系统的卷绕机和方法
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2022170437A1 (en) * 2021-02-11 2022-08-18 Venca Research, Inc. Compositions and methods for treating arrhythmogenic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
DE60129222T2 (de) * 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
EP2838888B1 (en) 2012-02-24 2017-04-12 ASD Therapeutics Partners LLC Thiadiazolidinediones as gsk-3 inhibitors

Also Published As

Publication number Publication date
ES2632428T3 (es) 2017-09-13
PT2838888T (pt) 2017-07-18
EP2838888B1 (en) 2017-04-12
HUE035089T2 (hu) 2018-05-02
AU2017248556A1 (en) 2017-11-09
HK1207366A1 (en) 2016-01-29
CA2865351C (en) 2019-08-20
EP2838888A1 (en) 2015-02-25
JP2017081974A (ja) 2017-05-18
CA2865351A1 (en) 2013-08-29
US20150038538A1 (en) 2015-02-05
US9371299B2 (en) 2016-06-21
US9469618B2 (en) 2016-10-18
US20160257660A1 (en) 2016-09-08
IN2014DN07885A (enExample) 2015-04-24
JP6518270B2 (ja) 2019-05-22
AU2013224041B2 (en) 2017-08-24
AU2017248556B2 (en) 2018-08-09
ZA201406225B (en) 2016-05-25
JP6073377B2 (ja) 2017-02-01
NZ630615A (en) 2015-09-25
HRP20170964T1 (hr) 2017-10-06
SI2838888T1 (sl) 2017-09-29
DK2838888T3 (en) 2017-07-17
WO2013124413A1 (en) 2013-08-29
PL2838888T3 (pl) 2017-12-29
AU2013224041A1 (en) 2014-09-25
JP2015508092A (ja) 2015-03-16
LT2838888T (lt) 2017-08-10

Similar Documents

Publication Publication Date Title
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
IN2014DN07885A (enExample)
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
EA201691940A1 (ru) Новые соединения
SA518391624B1 (ar) Ror- منظمات جاما
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CY1119227T1 (el) Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
IN2014DN09352A (enExample)
CY1118682T1 (el) Ενωσεις πυραζολης ως αναστολεις του υποδοχεα σιγμα
IN2014DN09348A (enExample)
MX376062B (es) Agonistas del receptor muscarinico.
EA201591686A1 (ru) Пиридинильные и конденсированные пиридинильные производные триазолона
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
EA201700042A1 (ru) Соединения имидазопиридазина
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2